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Abstract 
Objective: Periodic limb movements during sleep (PLMS) are sleep phenomena characterized 
by periodic episodes of repetitive stereotyped limb movements. The aim of this study was to 
describe the prevalence and determinants of PLMS in a middle-to-older age general population. 
Methods: Data from 2162 subjects (51.2% women, mean age 58.4±11.1 years) participating in a 
population-based study (HypnoLaus, Lausanne, Switzerland) were collected. Assessments 
included laboratory, socio-demographic, personal and treatment history, and full 
polysomnography at home. PLMS index (PLMSI) was determined and a PLMSI>15/h was 
considered as significant. 
Results: Prevalence of PLMSI>15/h was 28.6% (31.3% in men, 26% in women). Compared to 
subjects with a PLMSI≤15/h, subjects with a PLMSI>15/h were older (p<0.001), predominantly 
males (p=0.007), with a higher proportion of restless legs syndrome (RLS, p<0.001), a higher 
BMI (p=0.001), and a lower mean glomerular filtration rate (p<0.001). Subjects with a 
PLMSI>15/h also had a higher prevalence of diabetes, hypertension, and betablocker or hypnotic 
treatments. The prevalence of antidepressant use was higher, but not statistically significant 
(p=0.07).  Single nucleotide polymorphisms (SNP) within BTBD9 (rs3923809), TOX3 
(rs3104788) and MEIS1 (rs2300478) genes were significantly associated with PLSMI>15/h. 
Conversely, mean hemoglobin and ferritin levels were similar in both groups. In the multivariate 
analysis, age, male gender, antidepressant intake, RLS and rs3923809, rs3104788 and rs2300478 
SNPs were independently associated with a PLMSI>15/h. 
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Interpretation: PLMS are highly prevalent in our middle-age European population. Age, male 
gender, RLS, antidepressant treatment and specific BTBD9, TOX3 and MEIS1 SNPs distribution 
are independent predictors of a PLMSI >15/h. 
 
 
 
Keywords: Periodic limb movements; polysomnography; restless legs syndrome   
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Introduction  
Periodic limb movements of sleep (PLMS) are sleep-related phenomena characterized by  
periodic episodes of repetitive and highly stereotyped limb movements, which most often occur  
in the lower extremities. PLMS can be associated with brief arousals or full awakenings from  
sleep[1], and nearly all PLMS are accompanied by an autonomic reaction [2].  
PLMS are frequently seen in restless legs syndrome (RLS), and excessive PLMS represents a  
supportive criterion for the diagnosis of RLS [3]. PLMS have been documented in other sleep  
disorders, such as sleep disordered breathing [4], narcolepsy[5] and REM sleep behavior  
disorder[6], as well as in several medical conditions, like renal failure [7], essential  
hypertension[8], Parkinson’s disease[9], or associated with medication intake (in particular  
antidepressants and neuroleptics)[10]. Excessive PLMS have also been proposed as an  
independent cause of sleep disturbance. Periodic limb movement disorder (PLMD) is defined as  
the presence of >15 PLMS per hour and a complaint of insomnia and/or excessive daytime  
sleepiness with no other explanation for these symptoms[1]. In other cases, it is the bed partner  
who complains of being disturbed by these movements[1]. Furthermore, PLMS may be present  
without any complaint of disturbed sleep or daytime sleepiness, especially in elderly subjects.  
Although the clinical relevance of PLMS is not completely established, evidence is emerging  
that, in addition to disturbing sleep, PLMS could be associated with an increased risk of  
cardiovascular disease by increasing sympathetic nervous system activity[11], even though a  
conclusive association and causality remains to be demonstrated[12].  
Page 5 of 40
John Wiley & Sons
Annals of Neurology
This article is protected by copyright. All rights reserved.
6 
 
PLMS are hypothesized to be related to dopaminergic dysfunction[13], explaining their frequent  
association with disorders involving dopaminergic transmission and the reduction of PLMS with  
dopaminergic agents[14].   
Previous studies identified potential determinants of PLMS such as age, gender, coffee intake,  
use of hypnotics, although sometimes with conflicting results [15-17], probably due to the  
methods used to determine the presence of PLMS. A genetic predisposition has also been shown  
both in patients with RLS[18] and in the general population[17, 19], in particular with a common  
variant in an intron of the BTBD9 gene on chromosome 6p21.2.  
Studies of PLMS were carried out mostly in selected clinical populations (particularly in patients  
with RLS). Conversely, only a few used polysomnography (PSG) to determine the prevalence of  
PLMS in the general population [16, 17, 19], some using questionnaires or telephone  
interviews[15]. Finally, not all earlier studies used the current scoring criteria and cut-offs to  
determine the presence of PLMS. Thus, the prevalence and determinants of PLMS in the general  
population are not well defined. Yet, it is important to determine their prevalence and their  
determinants, in order to assess their possible pathophysiology and their clinical significance.  
The aim of the present study was thus to (1) estimate the prevalence of PLMS >15/h in the  
general population, and (2) to identify associated risk factors.  
  
Methods  
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Subjects  
The HypnoLaus Sleep Cohort study included subjects of the population-based  
CoLaus/PsyCoLaus Cohort study described previously [20-22]. Briefly, the CoLaus/PsychoLaus  
study included a random sample of 6733 subjects (range age: 35-75 years) selected from the  
residents of Lausanne city (Switzerland) between 2003 and 2006. The distribution of age groups,  
gender, and zip codes of participants were similar to the source population [20]. During the first  
follow up of the cohort, five years after the initial phase, all subjects who participated underwent  
a new physical (n=5064) and psychiatric (n=4000) examination. HypnoLaus evaluated the  
subjective and objective sleep characteristics in a random subset of this population. Sleep-related  
complaints and habits were investigated using several questionnaires among which the  
International Restless Legs Syndrome Study Group (IRLSSG) criteria for the diagnosis of RLS  
[23]. All subjects had a complete PSG at home. In the morning following the polysomnographic  
recording participants completed a questionnaire providing information about the quality of their  
sleep in the previous night, the amount of alcohol consumed 4 hours before going to bed, and  
their current medication.  
CoLaus/PsyCoLaus and HypnoLaus were approved by the Ethics Committee of the University of  
Lausanne and a written informed consent was obtained from all participants.  
  
Polysomnography  
During a visit at the Center for Investigation and Research in Sleep (Lausanne University  
Hospital, Switzerland), trained technicians equipped the subjects with the PSG recorder  
(Titanium, Embla
®
 Flaga, Reykjavik, Iceland) between 5 and 8 PM. All sleep recordings took  
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place in the subjects’ home environment and included a total of 18 channels, in accordance with 
2007 American Academy of Sleep Medicine (AASM) recommended setup specifications[24]: 
six electroencephalography, two electrooculography, three surface electromyography (one 
submental, two for right and left anterior tibialis muscles), one for electrocardiogram, nasal 
pressure, thoracic and abdominal belts, body position, oxygen saturation and pulse rate. Surface 
leg electrodes were placed longitudinally and symmetrically around the middle of the muscle so 
that they were 2 to 3 cm apart or 1/3 of the length of the anterior tibialis muscle, whichever was 
shorter. Separate channels for both legs were used. 
All PSG recordings were visually scored by two trained sleep technicians (DA and NT) using 
Somnologica software (Version 5.1.1, by Embla
®
 Flaga, Reykjavik, Iceland) and reviewed by a 
trained sleep physician (JHR). Random quality checks were performed by a second physician 
(RH). Quality control for concordance rate between the two PSG scorers was implemented 
periodically to ensure that both scorers achieved at least a 90% level of agreement for sleep 
stages, PLMS and respiratory events and an 85% level of agreement for arousals[25]. 
Sleep stages were scored in 30-sec epochs according to the 2007 AASM criteria[24]. Apneas, 
hypopneas and respiratory effort-related arousals were scored according to the 2012 AASM 
criteria[26]. The average number of apneas/hypopneas per hour of sleep (apnea-hypopnea index 
[AHI]) was calculated. 
Periodic leg movements were scored according to the official World Association of Sleep 
Medicine (WASM) standards [27] by the following strict criteria: (1) duration between 0.5 to 10 
sec; (2) minimum amplitude >8 µV in EMG voltage above resting EMG; (3) end of the event 
when the EMG decreased to <2 µV above the resting level and remained below that value for 0.5 
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s; (4) interval between 5 and 90 sec between leg movement onsets; (5) movements had to be part 
of a series of ≥4 consecutive movements meeting these criteria and (6) legs movements on 2 
different legs separated by less than 5 sec between movement onsets were counted as a single leg 
movement. Leg movements were not scored as PLMS if occurring at the end (±0.5 s) of a 
respiratory event, defined as the beginning of the first breath that approximated the baseline 
breathing amplitude. The periodic leg movement in sleep index (PLMSI) was calculated by 
dividing the total number of PLMS by total sleep time in hours. Consistent with the ICSD-3 
criteria, a PLMSI>15/h was used as the cutoff criterion for elevated PLMSI [1]. 
Arousals were scored using standard criteria if there was an abrupt shift of EEG frequency 
including alpha, theta and/or frequencies greater than 16 Hz (but not spindles) that lasts at least 3 
sec, with at least 10 sec of stable sleep preceding the change. Scoring of arousal during REM 
required a concurrent increase in submental EMG lasting at least 1 sec [24]. Periodic leg 
movements were also quantified based on whether they were associated with an arousal. An 
arousal and a PLMS were considered associated if there were <0.5 sec between the end of one 
event and the onset of the other event, regardless of which was first [27]. 
 
Clinical and Laboratory Measurements 
Blood pressure (BP) was measured in triplicate on the left arm and values averaged between the 
last two readings. Arterial hypertension was defined as a systolic BP (SBP) ≥140 mmHg and/or a 
diastolic BP (DBP) ≥90 mmHg or current use of antihypertensive medication. The body-mass 
index (BMI) was calculated and subjects were classified as overweight if their BMI was between 
25 and 30 kg/m
2
 and obese if BMI ≥30 kg/m
2
. Smoking habit was self-reported and was 
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dichotomized as current smoker/ex-smoker or never-smoker. Alcohol drinking was dichotomized 
as currently drinking or no alcohol consumption. Caffeine intake was estimated based on the 
number of cups recorded per day. Medication use at the time of sleep studies was recorded and 
coded according to the World Health Organization ATC classification 
(http://www.whocc.no/atcddd). We considered as “hypnotics” benzodiazepines and “Z-drugs” 
taken at night with a hypnotic purpose, and “benzodiazepines” taken during the day (for treating 
anxiety). 
Blood samples were taken in the fasting state for biological measurements. Diabetes was defined 
as a fasting blood glucose level ≥7 mmol/L (126 mg/dL) or current use of antidiabetic 
medication. Kidney function was measured by the estimated glomerular filtration rate (eGFR) 
calculated with the CKD-Epidemiology collaboration (CKD-EPI) equation[28], using creatinine 
from a morning fasting venous blood sample. Albuminuria was measured as albumin-to-
creatinine ratio on a morning urinary spot. Participants were categorized as having either normal 
kidney function (eGFR ≥60 ml/min/1.73m
2
 without albuminuria), chronic kidney disease (CKD) 
Stage 1-2 (eGFR ≥60 ml/min/1.73m
2
 with albuminuria) or CKD Stage 3 (eGFR 30-60 
ml/min/1.73m
2
), according to the Kidney Disease-Improving Global Outcomes (KDIGO) 
classification[29]. Iron status was evaluated by the hemoglobin levels and red blood cell 
distribution width (RDW, an estimation in percent of the average distribution of red blood cell 
diameter, the value of RDW increasing in relation to iron deficiency[30]). We chose the RDW 
value >14.5% as a tool to indirectly detect iron deficit[30]. Using a case-cohort approach ferritin 
was measured in a subsample (n=619) randomly selected by stratified sampling from the 
HypnoLaus population, according to gender and 10-years age interval group. Multiple 
imputation was used to make inference to the whole cohort [31].  
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Genotyping 
We used CoLaus/PsyCoLaus genome-wide genotype data and imputation, that has been 
described elsewhere [32]. Briefly, genotypes were measured on Affymetrix 500k array and only 
autosomal SNPs present in HapMap release 21 (390,631 measured scaffold SNPs) were used for 
imputation. Imputation was performed in 5435 CoLaus/PsyCoLaus participants using the method 
of Marchini et al.[33], using IMPUTE version 0.2.0. In total, 1594 subjects had both imputed 
genotype data and PLMSI measurements. Based on this analysis and in previously identified 
genetic determinants of PLMS [17-19] we examined candidate regions/single nucleotide 
polymorphisms (SNPs) and extracted genotype data for BTBD9 (rs3923809 [18], r
2
-hat=0.96), 
TOX3/BC034767 (rs3104788, r
2
-hat=1), MEIS1 (rs12469063 [17], r
2
-hat=0.97; rs2300478[19] 
is in high LD (0.95)), MAP2K5/SKOR1 (rs1026732[19] (r
2
-hat=1), rs6494696[17], in perfect 
LD), and PTPRD (rs1975197[17] (r
2
-hat=1), rs10977209 [discovered in this analysis] (r
2
-
hat=0.91)). 
 
Statistical Analyses 
Statistical analyses were performed using Stata version 11 (StataCorp, College Station, TX, 
USA), R (R Core Team, 2014)[34] and Matlab (The MathWorks Inc. version 8.3.0.532 
(R2014a)). For descriptive statistics, continuous variables were summarized as mean±standard 
deviation (SD) or median±interquartile range (IQR), while categorical variables were 
summarized as number of subjects and percentages. We compared subjects with PLMSI ≤15/h 
and subjects with PLMSI>15/h using the χ2 test, Student’s t test, or Wilcoxon’s rank-sum test. 
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We used Cohen’s d to calculate the effect size of the differences between participants who  
underwent polysomnography and those who did not. We performed multiple imputation for the  
analysis of the case-cohort data[31] using the mice package[35] in order to impute ferritin levels.  
Then we used logistic regression models to assess the association between demographic, clinical  
and genetic variables and a PLMSI>15/h.  
Logistic regression was applied for 2,557,249 SNPs genome-wide, correcting for age and gender.  
Effect size, standard error and P-value were calculated for each SNP. We also applied linear  
regression for inverse normal quantile transformed raw PLMSI values using the same covariates.  
The assessment of PLMS in the presence of sleep disordered breathing (SDB) is challenging by  
the fact that leg movements may be triggered by the respiratory events and are not part of a  
PLMS sequence. For this reason we also analyzed PLMS determinants in subjects without  
significant SDB, with an AHI cut-off value of 15/h[1].  
Statistical significance was considered for a two-sided test p-value <0.05.  
  
Results  
  
Description of the Sample  
Of 3043 consecutive subjects from the first follow-up of the population-based  
CoLaus/PsyCoLaus cohort study, 2168 (71.1%) agreed to have a PSG at home. Technical  
problems resulting in insufficient data for PSG scoring were encountered in 60 cases (2.8%); 54  
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subjects accepted to repeat the PSG and 6 subjects declined, resulting in 2162 participants 
(51.2% women, mean age 58.4±11.1 years) included in the final analysis (Figure 1). Compared 
with the whole CoLaus/PsyCoLaus cohort, subjects who underwent PSG were similar in terms of 
age, sex, BMI, and ethnic origin, and they were representative of Lausanne’s general 
population[20].  
 
General Characteristics 
For the whole population, the median (P05–P95) PLMSI was 2 (0-64)/h, the upper 5% centile 
was 73/h for men and 53/h for women, with a median duration of 2 (1-5) sec, and 18 (0-76)% 
were associated with an EEG arousal. PLMS were more frequent during stages 1 (median 
PLMSI: 15 (0-82)/h) and 2 (median PLMSI: 17 (0-90)/h), less frequent during stage 3 (median 
PLMSI: 9 (0-121)/h) and rare during REM sleep (median PLMSI: 0 (0-31)/h); ANOVA for 
PLMSI in stage 1, stage 2, stage 3, REM sleep, p<0.001).  
 
Prevalence of PLMSI>15/h 
The overall prevalence of PLMSI>15/h was 28.6% (31.3% in men and 26.0% in women) in our 
middle to older aged general population sample. In the group with PLMSI>15/h, PLMS were 
present during all stages of NREM sleep, persisting during stage 3, but more rarely during REM 
sleep (p<0.001), and 14% of them were associated with an EEG-arousal. 
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Determinants of PLMSI>15/h 
Compared to subjects with PLMSI≤15/h, subjects with a PLMSI>15/h were significantly older, 
more frequently men, had a higher BMI and a higher prevalence of overweight and obesity. 
Subjects with PLMSI>15/h also had an increased prevalence of hypertension, diabetes and a 
higher rate of postmenopausal women. For women, there were no significant differences 
between groups concerning the number of pregnancies (Table 1). 
Regarding drug treatment, subjects with a PLMSI>15/h reported more frequently taking 
hypnotics and betablockers, while borderline associations were found for antidepressants, 
antihistaminics and neuroleptics (Table 1). On the other hand, no differences were found for 
consumption of caffeine, alcohol or tobacco (Table 1). 
Subjects with a PLMSI>15/h reported more RLS-related symptoms (Table 1). However, three 
quarters of them did not complain about RLS. When stratifying PLMS+ subjects according to the 
presence or absence of RLS symptoms, RLS+ was associated with a higher proportion of 
women, psychotropic drug (neuroleptics, hypnotics, antidepressants and benzodiazepine) use and 
a lower AHI (Supplementary table 1). 
Subjects with a PLMSI>15/h had a higher AHI (Table 2). A weak correlation was found 
between the PLMSI and the AHI (ρ=0.101, p<0.05), but this association disappeared when 
adjusting for age (p=0.575). 
Concerning iron-related measurements, subjects with PLMSI >15/h had a mildly increased 
RDW, while no significant differences were found between groups regarding hemoglobin or 
ferritin levels, or regarding the percentage of subjects with ferritin <100 ng/mL (Table 2). 
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Although the percentage of subjects with serum ferritin <50 ng/mL tended to be higher in 
subjects with PLMSI>15/h, this difference was not statistically significant (p=0.155). No 
significant correlation was noted between the PLMSI and ferritin levels (p=0.063). Otherwise, a 
PLMSI>15/h was associated with lower glomerular filtration rate and higher percentage of CKD 
(Table 2). 
GWAS analysis revealed BTB domain–containing 9 (BTBD9) gene as the region showing 
genome-wide significant association, and confirmed strong association of rs3923809 SNP with 
PLMSI[18]. The association between the A allele of rs3923809 and PLMSI>15/h was genome-
wide significant at p=9.10e-10. This association was further confirmed when subjects were 
grouped according to genotype into AA homozygotes (746 subjects, 46.8%), AG heterozygotes 
(678 subjects, 42.5%), and GG homozygotes (170 subjects, 10.7%) (Supplementary table 2). 
Note that these are (rounded) expected counts taking genotype uncertainty into account. For 
marker rs3923809, the PLMSI was greater in AA homozygotes than in AG heterozygotes 
(16.42±0.87 vs. 11.87±0.85/h, p=1.84e-4) and greater in AG heterozygotes than in GG 
homozygotes (11.87±0.85 vs. 6.50±1.23, p=3.39e-4). The PLMSI in AA homozygotes was 
almost threefold higher than in non A carriers (16.42 vs 6.50, p=5.33e-11). We also examined 
other candidate regions/SNPs. For dichotomized PLMS (PLMSI>15/h versus PLMSI ≤15/h) we 
found significant associations for rs3104788 (TOX3) and for rs2300478 (MEIS1) 
(Supplementary table 2). When treating PLMSI as a continuous outcome variable, many more 
showed stronger replicating tendencies: TOX3 SNP rs3104788 (P=1.98e-05), MEIS1 SNP 
rs2300478 (P=0.0452), MAP2K5 SNP rs1026732 (P=4.56e-03), PTPRD SNP rs1975197 
(P=0.0141). Gene-based analysis also confirmed TOX3, MAP2K5 and PTPRD at 5% FDR. 
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Interestingly, we found another SNP (not in LD with rs197519) with stronger association in 
PTPRD (rs10977209 (P = 7.27e-04)) surviving 5% FDR. 
 
Multivariate analysis of the determinants of PLMSI>15/h 
As a next step, we examined the association of a PLMSI>15/h and predetermined variables from 
the univariate analysis and other previously reported possible determinants, using multiple 
imputation and a multiple variable logistic regression analysis, in order to determine independent 
predictors.  
The factors significantly and independently associated with a PLMSI>15/h were: age (OR (95% 
CI): 1.07 (1.05 - 1.08), p<0.001), male gender (OR: 1.56 (1.16- 2.09), p=0.003), antidepressant 
drugs intake (OR: 1.55 (1.02- 2.35), p=0.040), RLS (OR: 1.92 (1.40- 2.64), p<0.001) and the 
alleles of rs3923809, rs3104788 and  rs2300478 (Table 3). The strongest genetic association was 
found for the allele A of rs3923809 of the BTBD9 gene, with a risk ratio for homozygous (AA) 
compared to homorozygous (GG) carriers estimated at 3.52 (95% CI 2.12-5.86, p<0.001). The 
AHI showed a negative association (OR: 0.88 (0.77- 0.99), p<0.042). Conversely, no significant 
independent associations were found for BMI, hypertension, diabetes, alcohol, caffeine or 
tobacco consumption, or for the ferritin levels (Table 3).  
Restricting the analysis to subjects without significant SDB (AHI <15/h) yielded similar results, 
with the additional findings that BMI became independently associated with the presence of 
PMLS >15/h, whereas allele distribution of the rs2300478 SNP was no longer significantly 
associated (Supplementary table 3).  
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Discussion  
To the best of our knowledge, the HypnoLaus Sleep Cohort study is the largest study assessing  
the prevalence and determinants of PLMS in a population-based sample. We found a high  
prevalence of PLMS in the general population: 28.6% of our sample had a PLMSI>15/h (31.3%  
of men and 26.0% of women). When compared to subjects with a PLMSI≤15/h, subjects with a  
PLMSI>15/h were older, with a higher percentage of men and postmenopausal women and a  
higher BMI. A higher percentage of subjects had RLS, diabetes, hypertension and more of them  
were taking beta-blockers and antidepressants. Their mean glomerular filtration rate was lower,  
but the mean ferritin level was similar in both groups. We also found significant associations  
with allele distribution of SNPs within BTBD9 (rs3923809), TOX3 (rs3104788) and MEIS1  
(rs2300478) genes. In the multivariate analysis, age, male gender, antidepressant intake, RLS  
and alleles of rs3923809, rs3104788 and rs2300478 were independently associated with a  
PLMSI higher than 15/h.  
  
  
Prevalence of PLMSI>15/h  
In our study, analyzing data from 2162 subjects representative of the adult general population of  
Lausanne, we found a prevalence of PLMSI >15/h of 28.6%. Scofield et al. reported a  
prevalence of 7.6% in a community-based sample of 592 participants drawn from the general  
population of Detroit Tri-County using standardized PSG criteria[16]. One possible explanation  
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for this difference is the racial/ethnic distribution in the Scofield’s study, with a large African 
American population, in which the prevalence of PLMS was found to be lower, whereas subjects 
participating in our study were almost exclusively of European origin. In addition, participants in 
their study were younger. Finally only an anterior tibialis EMG was used to record PLMS 
(instead of two separate channels for both legs as in our study), and leg movements were 
considered when their duration was between 0.5 to 5 sec (instead of between 0.5 to 10 sec as 
proposed in current scoring criteria[1, 24, 27]). These two technical factors could have 
contributed to an undervaluation of the presence of PLMS in Scofield’s study. The estimate of 
the prevalence we found is closer to the 33% reported by Moore et al.[17].  In this study authors 
analyzed PSG data from 1090 participants on the Wisconsin Sleep Cohort, an epidemiological 
prospective study from the general population that included an enriched selection of people at 
risk for SDB. In this study a single-leg EMG channel was processed, and an automatic detector 
allowed recognition of PLM using a previously validated algorithm and slightly modified AASM 
scoring criteria. Recently, Winkelman et al. using 1993 AASM scoring criteria reported a much 
higher prevalence of PLMI ≥15 (61%), in participants of the Osteoporotic Fractures in Men 
Study probably due to the fact that they analyzed data exclusively from community-dwelling 
men 65 years or older [19].   
 
Determinants of PLMSI>15/h 
As previously described, we found in our study as association between increasing age and PLMS 
prevalence[16]. PLMS rarely occurs in children and adolescents without associated medical 
conditions[36], whereas in the elderly, PLMS are frequently observed, even in subjects without 
any sleep disturbance[37, 38].  
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In our study, male gender was associated with a higher prevalence of PLMS. Ohayon et al. 
reported a higher prevalence in women, but that study was based only on telephone interviews 
without PSG recordings to confirm the presence of PLMS[15]. Studies using objective methods 
to determine PLMS (either PSG[16, 17] or actigraphy[39]) also found a higher prevalence in 
males. 
The occurrence of PLMS has been described in association with the intake of several 
medications, in particular with drugs impairing dopaminergic transmission and serotoninergic 
agents. The low frequency use of certain medications in our population, as neuroleptics, prevents 
from drawing definitive conclusions concerning a possible association with these specific drugs. 
Yet, we could show that the intake of antidepressants was independently associated with a 
PLMSI>15/h. Yang et al., analyzed data from 274 patients treated with antidepressants and 
found also a significant increase of PLMS during treatment, in particular in those treated with 
selective serotonin reuptake inhibitors and with venlafaxine[10]. Most other antidepressants can 
also induce or increase PLMS [40-42], with the exception of bupropion that seems to reduce 
them [10, 43].  
Subjects with PLMS fulfilled more frequently the four cardinal diagnostic features of RLS[23]. 
This association between RLS and PLMS is well established and the presence of excessive 
PLMS supports the diagnosis of RLS [3]. This suggests RLS and PLMS may share, to some 
extent, the same pathophysiological origin. However, it must be stressed that RLS could be 
present without significant PLMS, and that as many as three quarters of subjects with a PLMSI 
>15/h did not complaint of RLS. In subjects with PLSMS>15/h, RLS symptoms were more 
frequent in women and were associated with the intake of psychotropic drugs and with lower 
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AHI. It is thus still unclear if RLS with and without PLMS correspond to different 
phenotypes[44]. 
In our study, we found a highly significant association between PLMSI and rs3923809, a 
common A/G single-nucleotide variation in an intron of BTBD9 gene on chromosome 6, 
pointing to a major genetic contribution to PLMS. The PLMS risk ratio for homozygous carriers 
(AA) to heterozygous carriers (AG) was estimated at 3.52, and the PLMI was correlated with the 
presence of allele A, homozygotes having almost threefold increase in leg movements per hour 
of sleep compared to non A carriers. Our data confirm the findings of Stefansson et al., who first 
described the association between rs3923809 and PLMS in subjects with RLS[18]. We also 
examined whether the genotype of this SNP modifies the association of clinically important risk 
factors (obesity, hypertension, diabetes, dyslipidemia), but no statistically significant interaction 
was observed. Two recent studies examined the association between PLM and single-nucleotide 
polymorphisms known to increase risk of RLS [17, 19]. We have also examined other candidate 
regions (including TOX3/BC034767, MEIS1, MAP2K5/SKOR1, and PTPRD). Three of them 
showed convincing (<5%FDR) evidence of association with PLMSI: PTPRD (rs10977209, 
p=7.27e-4), MAP2K5 (rs2241420, p=5.69e-4) and TOX3 (rs3104788, p=1.98e-5). Allele 
distribution of the TOX3 (rs3104788) and MEIS1 (rs2300478) SNPs were significantly 
associated with PLSMI>15/h, even if these represent much weaker associations with PLM than 
rs3923809. 
Stefansson et al. found an inverse correlation of the rs3923809 variant with iron stores, estimated 
by means of the ferritin index and the serum ferritin levels[18]. This finding is consistent with 
the suspected involvement of iron depletion in the pathogenesis of RLS, in which studies have 
clearly defined a role of brain iron deficiency in some patients with RLS, particularly in those 
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with early-onset symptoms[45]. If a significant correlation has been shown between serum  
ferritin levels and RLS severity, no clear relationship between declining iron status and PLMS  
severity have been demonstrate[46].   
  
  
Strengths and Limitations  
The major strengths of our study is its population-based design, the large sample size, the  
availability of detailed information on a large number of demographic, clinical and genetic  
variables and the use of PSG to determine the presence of PLMS and sleep co-morbidities.  
Nevertheless, we have to acknowledge potential limitations. First, our results are based on a  
single PSG, and an individual inter-night variability has been demonstrated in PLMS  
frequency[47]. The assessment of PLMS was performed using current scoring criteria of leg  
movements proposed by the WASM. The use of other scoring criteria, as those established by  
the AASM, could have led to different results in terms of frequency and prevalence of PLMS.  
Although these two major international scoring guidelines differ in their definition of respiratory  
related leg movements (LMs) both specifically exclude LMs occurring at the end (± 0.5 s) of  
respiratory events from the scoring of PLMS. It is however often difficult to differentiate  
movements supposed to be secondary to the arousal at the end of respiratory events to PLMS  
occurring independently and it has been shown that respiratory related LMs can occur in a time  
interval longer than the 0.5 sec proposed by the current criteria[48]. It is therefore possible that  
some of the LMs that we have considered as PLMS were actually respiratory related.  However,  
in the multivariate analysis, the AHI showed a negative association with the PLMSI, and when a  
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subgroup with an AHI <15/h was analyzed we found the same determinants of PLMSI >15/h as 
in the whole population.  We evaluated iron status with the ferritin levels (that reflects the 
storage iron compartment). We cannot exclude that other measures of iron, such as the serum 
transferrin receptor (that reflects the functional iron compartment) or a combination of indices 
could have given a clearer picture of functional iron status[49]. Finally, we included in our study 
subjects aged 40–85 years old only, almost exclusively of European origin. Thus, generalization 
of findings to younger people or to people from other ethnic backgrounds is limited. 
 
Conclusions 
PLMS are highly prevalent in the general population. Age, male gender, antidepressant intake, 
RLS and alleles rs3923809 of the BTBD9,  rs3104788 of the TOX3 and rs2300478 of the MEIS1 
genes are independent predictors of a PLMSI >15/h. Further studies are needed to evaluate the 
clinical impact of PLMS. 
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Figure legends 
Figure 1: Studied population 
PSG: Polysomnography   
 
Figure 2: Prevalence of PLMSI throughout the entire range of potential cut-off values. 
PLMSI: Periodic limb movements during sleep index. 
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Table 1. Demographic and clinical characteristics of the study population, stratified by 
the presence of PLM. 
 TOTAL PLMSI ≤15/h PLMSI >15/h P value 
N (%)  N=2162 N=1544 (71.4%) N=618 (28.6%)  
Age (years)* 59 (11) 57 (11) 64 (11) <0.001 
Gender (women)  1106 (51.2) 818 (53.0) 288 (46.6) 0.007 
For women     
Postmenopausal 776 (71.8) 535 (67.2) 241 (84.9) <0.001 
Number of pregnancies ** 2 (1-3) 2 (1-3) 2 (1-4) 0.770 
BMI (kg/m
2
)* 25.7 (4.2) 25.5 (4.2) 26.1 (4.3) 0.001 
BMI ≥25 (kg/m
2
) 1132 (52.4) 773 (50.1) 359 (58.1) 0.001 
BMI ≥30 (kg/m
2
) 291 (13.5) 190 (12.3) 101 (16.3) 0.016 
Diabetes 214 (9.9) 126 (8.2) 88 (14.2) <0.001 
Hypertension 897 (41.5) 560 (36.3) 337 (54.5) <0.001 
Restless legs syndrome 321 (18.0) 191 (15.0) 130 (25.3) <0.001 
Treatment     
Neuroleptics 41 (1.9) 24 (1.6) 17 (2.8) 0.069 
Hypnotics 187 (8.8) 121 (8.0) 66 (10.8) 0.037 
Antidepressants  209 (9.7) 138 (8.9) 71 (11.5) 0.070 
Betablockers 184 (8.5) 108 (7.0) 76 (12.3) <0.001 
Benzodiazepines  117 (5.4) 85 (5.5) 32 (5.2) 0.761 
Antihistaminics*** 21 (1.0) 19 (1.2) 2 (0.3) 0.054 
Alcohol consumption 1825 (85.2) 1301 (85.0) 524 (85.6) 0.729 
Coffee consumption 2021 (93.5) 1435 (92.9) 586 (94.8) 0.135 
No 141 (6.6) 106 (7.2) 32 (5.2)  
1-3 cups/day 1412 (66.4) 987 (65.1) 425 (69.6)  
4-6 cups/day 500 (23.5) 369 (24.3) 131 (21.4)  
>6 cups/day 74 (3.5) 51 (3.4) 23 (3.8)  
Tobacco consumption 398 (18.6) 290 (19.0) 108 (17.7) 0.484 
     
PLMSI: Periodic limb movements during sleep index; BMI: body mass index;  *Mean (SD);  **median 
(P05 – P95);  *** Fisher’s exact test. P value: PLMSI ≤15/h vs. PLMSI >15/h. 
Page 31 of 40
John Wiley & Sons
Annals of Neurology
This article is protected by copyright. All rights reserved.
32 
 
 
Table 2. Polysomnographic features of PLMS and biological characteristics of the study 
population, stratified by the presence of PLM. 
 
 TOTAL PLMSI ≤15/h PLMSI >15/h P value 
N (%)  N=2162 N=1544 (71.4%) N=618 (28.6%)  
PLMSI (n/h) * 2 (0-64) 0 (0-12) 34 (17-95) <0.001 
LM mean duration in PLMS (sec)
1 
* 2 (1-5) 2.1 (1.0-4.4) 2.5 (1.5-4.7) <0.001 
% of LM in PLMS with arousal (%)
1
 18 (0-76) 22 (0-86) 14 (0-57) <0.001 
PLMS arousal index (n/h)
1 
* 2 (0-16) 1 (0-6) 5 (0-22) <0.001 
AHI * 10 (1-51) 9 (1-50) 12 (1-53) <0.001 
Glomerular filtration rate (ml/min) ** 3.0 (0.7) 3.1 (0.7) 2.9 (0.7) <0.001 
Kidney function categories    <0.001 
No CKD 1478 (84.0) 1083 (86.4) 395 (78.1)  
Stages 1-2 (GFR ≥60 ml/min) 145 (8.2) 97 (7.7) 48 (9.5)  
Stage 3 (GFR 30-60 ml/min) 137 (7.8) 74 (5.9) 63 (12.4)  
Hemoglobin (g/l) ** 145 (12.0) 144.6 (11.8) 145.3 (12.6) 0.290 
Red blood cell distribution width (%) 13.3 (0.8) 13.3 (0.7) 13.4 (0.9) 0.002 
Ferritin, ng/mL * (case-cohort) 153 (30-511) 158 (54-644) 153 (28-511) 0.916 
Ferritin <50 ng/mL (case-cohort) 58 (9.8) 16 (7.5) 42 (11.1) 0.155 
Ferritin <100 ng/mL (case-cohort) 173 (29.3) 58 (27.2) 115 (30.5) 0.401 
____________________________________________________________________________________ 
PLMSI: Periodic limb movements during sleep index; AHI: apnoea/hypopnea index; CKD: chronic kidney 
disease; GFR: glomerular filtration rate. 
1
Results for PLMSI >0; *Median (P05 – P95); **mean (SD). P 
value: PLMSI ≤15/h vs. PLMSI >15/h. 
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Table 3: Association between demographic, clinical and genetic features and PLMSI 
>15/h. 
 OR (95% CI) P value 
Age (per one year increase) 1.068 (1.054 - 1.083) <0.001 
Gender (man) 1.560 (1.163- 2.092) 0.003 
BMI (per one unit increase) 1.027 (0.993- 1.063) 0.119 
Hypertension (yes vs. no) 1.180 (0.887- 1.569) 0.255 
Diabetes (yes vs. no) 1.135 (0.750- 1.719) 0.549 
Restless legs syndrome (yes vs. no) 1.916 (1.391- 2.638) <0.001 
AHI (log) 0.876 (0.771- 0.995) 0.042 
Alcohol consumption (yes vs. no) 1.170 (0.811- 1.688) 0.400 
Coffee consumption (reference: 0 cups)    
1-3 cups/day 1.386 (0.780- 2.464) 0.266 
4-6 cups/day 1.182 (0.639- 2.186) 0.595 
6+ cups/day 1.878 (0.789- 4.473) 0.155 
Tobacco consumption (yes vs. no) 1.158 (0.833- 1.609) 0.383 
Antidepressant intake (yes vs. no) 1.551 (1.022- 2.354) 0.040 
Ferritin level 0.919 (0.742- 1.138) 0.448 
rs3923809 allele (reference: GG)    
 AG 1.994 (1.185- 3.354) 0.009 
 AA 3.521 (2.117- 5.856) <0.001 
rs3104788 allele (reference: CC)    
 TC 1.582 (1.135- 1.903) 0.013 
 TT 1.966 (1.621- 2.384) <0.001 
rs2300478 allele (reference: TT)    
 TG 1.428 (1.099- 1.856) 0.008 
 GG 1.596 (0.943- 2.699) 0.082 
 
BMI: body mass index; AHI: apnoea/hypopnea index. Statistical analysis by logistic regression models. 
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Supplementary table 1. Characteristics of the population with PLMSI >15/h, stratified by 
the presence of RLS. 
 PLMSI >15/h RLS - RLS +  P value 
N (%)  N=513  N=383 (74.7%) N=130 (25.3%)  
Age (years)* 64 (11) 64 (10) 63 (11) 0.209 
Gender (women)  249 (48.5) 172 (44.9) 77 (59.2) 0.005 
For women     
Postmenopausal     
Number of pregnancies **     
BMI (kg/m
2
)* 26.0 (4.4) 25.9 (4.3) 26.3 (4.7) 0.446 
BMI ≥25 (kg/m
2
) 290 (56.5) 217 (56.7) 73 (56.1) 0.920 
BMI ≥30 (kg/m
2
) 85 (16.6) 60 (15.7) 25 (19.2) 0.345 
Diabetes 70 (13.7) 49 (12.8) 21 (16.2) 0.335 
Hypertension 276 (53.8) 208 (54.3) 68 (52.3) 0.693 
Restless legs syndrome -- -- -- -- 
Treatment     
Neuroleptics 10 (2.0) 4 (1.1) 6 (4.6) 0.021 
Hypnotics 23 (4.5) 16 (4.2) 7 (5.4) 0.037 
Antidepressants  43 (8.5) 26 (6.9) 17 (13.2) 0.028 
Betablockers 63 (12.3) 46 (12.0) 17 (13.1) 0.749 
Benzodiazepines  26 (5.1) 12 (3.1) 14 (10.8) 0.001 
Antihistaminics*** 2 (0.4) 0 (0.0) 2 (1.5) -- 
Alcohol consumption 436 (85.2) 326 (85.1) 110 (85.3) 0.966 
Coffee consumption    0.473 
No 24 (4.7) 16 (4.2) 8 (6.2)  
1-3 cups/day 359 (70.1) 265 (69.4) 94 (72.3)  
4-6 cups/day 108 (21.1) 83 (21.7) 25 (19.2)  
>6 cups/day 21 (4.1) 18 (4.7) 3 (2.3)  
Tobacco consumption 422 (82.4) 320 (83.8) 102 (78.5) 0.170 
Mean PLMSI (n/h)  33 (17-97) 34 (17-90) 0.645 
LM mean duration in PLMS (sec)
1 
*  2 (1-5) 2 (1-5) 0.330 
% of LM in PLMS with arousal (%)  14 (0-57) 17 (0-62) 0.090 
PLMS arousal index (n/h)
1 
*  5 (0-20) 6 (0-27) 0.103 
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AHI *  12 (1-53) 10 (1-36) 0.021 
Glomerular filtration rate (ml/min) **     
Kidney function categories     
No CKD     
Stages 1-2 (GFR ≥60 ml/min)     
Stage 3 (GFR 30-60 ml/min)     
Hemoglobin (g/l) ** 144.6 (12.4) 145.1 (12.3) 142.9 (12.7) 0.159 
Red blood cell distribution width (%) 13.4 (0.9) 13.4 (0.8) 13.5 (1.1) 0.128 
Ferritin, ng/mL * (case-cohort)  155 (32-488) 145 (23-713) 0.495 
Ferritin <50 ng/mL (case-cohort) 33 (10.7) 21 (9.1) 12 (15.6) 0.108 
Ferritin <100 ng/mL (case-cohort) 93 (30.1) 65 (28.0) 28 (36.4) 0.166 
rs3923809 allele (BTBD9 gene)    0.851 
AA 255 (58.2) 192 (57.7) 63 (60.0)  
AG 160 (36.5) 124 (37.2) 36 (34.3)  
GG 23 (5.3) 17 (5.1) 6 (5.7)  
rs2300478 allele (MEIS1 gene)    0.717 
TT 224 (49.9) 167 (48.8) 57 (53.3)  
TG 195 (43.4) 152 (44.4) 43 (40.2)  
GG 30 (6.7) 23 (6.7) 7 (6.5)  
rs6494696 allele (MAP2K5 gene)    0.152 
GG 222 (49.3) 176 (51.3) 46 (43.0)  
GC 187 (41.6) 140 (40.8) 47 (43.9)  
CC 41 (9.1) 27 (7.9) 14 (13.1)  
rs2241420 allele (MAP2K5 gene)    0.371 
GG 270 (65.1) 212 (66.9) 58 (59.2)  
GA 128 (30.8) 93 (29.3) 35 (35.7)  
AA 17 (4.1) 12 (3.8) 5 (5.1)  
rs1975197 allele (PTPRD gene) ***    0.949 
GG 296 (65.8) 224 (65.3) 72 (67.3)  
GA 143 (31.8) 110 (32.1) 33 (30.8)  
AA 11 (2.4) 9 (2.6) 2 (1.9)  
rs10977209 allele (PTPRD gene) ***    0.691 
TT 332 (77.4) 249 (76.6) 83 (79.8)  
TC 88 (20.5) 68 (20.9) 20 (19.2)  
CC 9 (2.1) 8 (2.5) 1 (1.0)  
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PLMSI: Periodic limb movements during sleep index; RLS: Restless legs syndrome; BMI: body mass index; 
AHI: apnoea/hypopnea index; CKD: chronic kidney disease; GFR: glomerular filtration rate. 
1
Results for 
PLMSI >0 *Mean (SD); **median (P05 – P95); *** Fisher’s exact test. P value: PLMSI ≤15/h vs. PLMSI 
>15/h. 
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Supplementary table 2. Allele frequencies, stratified by the presence of PLMS. 
 TOTAL PLMSI ≤15/h PLMSI >15/h P value 
N (%)  N=2162 N=1544 (71.4%) N=618 (28.6%)  
rs3923809 allele (BTBD9 gene)    <0.001 
AA 746 (46.8) 485 (42.8) 261 (56.7)  
AG 678 (42.5) 502 (44.2) 176 (38.3)  
GG 170 (10.7) 147 (13.0) 23 (5.0)  
rs3104788 allele (TOX3 gene)    0.013 
TT 577 (32.9) 376 (30.9) 201 (37.4)  
TC 857 (48.8) 603 (50.0) 254 (47.2)  
CC 321 (18.3) 238 (19.6) 83 (15.4)  
rs2300478 allele (MEIS1 gene)    0.011 
TT 983 (56.2) 710 (58.5) 273 (50.8)  
TG 665 (38.0) 437 (36.0) 228 (42.5)  
GG 102 (5.8) 66 (5.4) 36 (6.7)  
rs6494696 allele (MAP2K5 gene)    0.298 
GG 803 (45.7) 542 (44.5) 261 (48.5)  
GC 783 (44.6) 554 (45.5) 229 (42.8)  
CC 169 (9.6) 121 (9.9) 48 (8.9)  
rs2241420 allele (MAP2K5 gene)    0.058 
GG 945 (59.5) 634 (57.7) 311 (63.3)  
GA 560 (35.2) 399 (36.3) 161 (32.8)  
AA 84 (5.3) 65 (5.9) 19 (3.9)  
rs1975197 allele (PTPRD gene)    0.620 
GG 1180 (67.3) 824 (67.8) 356 (66.2)  
GA 526 (30.0) 357 (29.4) 169 (31.4)  
AA 48 (2.7) 35 (2.9) 13 (2.4)  
rs10977209 allele (PTPRD gene)    0.147 
TT 1278  (75.8) 886 (75.5) 392 (76.3)  
TC 386 (22.9) 275 (23.4) 111 (21.6)  
CC 23 (1.4) 12 (1.0) 11 (2.1)  
PLMSI: Periodic limb movements during sleep index. Single nucleotide polymorphisms (SNP) are 
grouped according to gene (chromosome in parenthesis. P value: PLMSI ≤15/h vs. PLMSI >15/h. 
Page 37 of 40
John Wiley & Sons
Annals of Neurology
This article is protected by copyright. All rights reserved.
38 
 
Supplementary table 3: Association between demographic, clinical and genetic features  
and PLMSI > 15/h in participants with apnoea-hypopnoea index <15/h.  
 
OR (95% CI) P value 
Age (per one year increase) 1.070 (1.052 - 1.089) <0.001 
Gender (man) 1.527 (1.030- 2.266) 0.037 
BMI (per one unit increase) 1.057 (1.010- 1.106) 0.018 
Hypertension (yes vs. no) 1.199 (0.821- 1.751) 0.349 
Diabetes (yes vs. no) 1.706 (0.857- 3.396) 0.128 
Restless legs syndrome (yes vs. no) 1.938 (1.278- 2.940) 0.002 
AHI (log) 0.863 (0.708- 1.052) 0.144 
Alcohol consumption (yes vs. no) 1.081 (0.678- 1.726) 0.743 
Coffee consumption (reference: 0 cups) 
   
1-3 cups/day 1.287 (0.634- 2.606) 0.484 
4-6 cups/day 0.970 (0.452- 2.082) 0.937 
6+ cups/day 1.832 (0.642- 5.229) 0.258 
Tobacco consumption (yes vs. no) 1.071 (0.695- 1.651) 0.755 
Antidepressant intake (yes vs. no) 1.653 (0.908- 3.011) 0.100 
Ferritin 0.893 (0.571- 1.398) 0.638 
rs3923809 allele(reference: GG) 
   
AG 3.545 (1.600- 7.858) 0.002 
AA 4.845 (2.206- 10.641) <0.001 
rs3104788 allele (reference: CC) 
   
 TC 2.197 (1.314- 3.672) 0.003 
 TT 2.747 (1.599- 4.719) <0.001 
rs2300478 allele (reference: TT) 
   
 TG 1.326 (0.937- 1.876) 0.111 
 GG 1.390 (0.689- 2.805) 0.358 
  
BMI: body mass index; AHI: apnoea/hypopnea index. Statistical analysis by logistic regression models.  
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Figure 1: Studied population  
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